Federal Circuit Affirms that Tribal Immunity Is Not Available for Inter Partes Review

Jul 27, 2018

Reading Time : 2 min

Before the hearing, Allergan assigned its patents to the Saint Regis Mohawk Tribe (“the Tribe”). Under the agreement, Allergan received an exclusive grant-back license to the patents. After the assignment, the Tribe moved to terminate the IPRs based on sovereign immunity, citing two PTAB decisions immunizing the Universities of Florida and Minnesota under the 11th Amendment.2The Board denied the Tribe’s motion on various grounds, including that tribal sovereign immunity was not available in an IPR.3

On appeal, the Tribe argued that tribal sovereign immunity should apply in IPRs because they are contested, adjudicative proceedings. In response, Mylan argued, among other things, that IPR is more like an agency enforcement decision, where tribal immunity does not apply. The Federal Circuit acknowledged that IPR is a “hybrid proceeding” with “adjudicatory characteristics,” but ultimately concluded that it was insufficiently adjudicatory to confer sovereign immunity. Four factors drove the Federal Circuit’s conclusion: (1) the Director possesses broad discretion in the decision to institute; (2) the Board may continue review even if the petitioner chooses not to participate; (3) the rules controlling IPRs are substantially different from the Federal Rules of Civil Procedure, and; and (4) IPRs are not necessarily proceedings in which Congress contemplated tribal immunity to apply.

Although the Federal Circuit limited its holding to tribal sovereign immunity, the decision may have broader consequences for entities such as state universities that traditionally enjoy state sovereign immunity in IPRs. Indeed, the Federal Circuit noted the “many parallels” between tribal and state sovereign immunity. Given this language, it would not be surprising to see future challenges to state sovereign immunity in IPRs.

Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Akorn, Inc., Nos. 2018-1638, 2018-1639, 2018-1640, 2018-1641, 2018-1642, 2018-1643 (Fed. Cir. July 20, 2018)


1  Nos. 2018-1638, 2018-1639, 2018-1640, 2018-1641, 2018-1642, 2018-1643, slip op. (Fed. Cir. Jul. 20, 2018).

2  Reactive Surfaces LTD., LLP, v. Toyota Motor Corp., IPR2016-01914, IPR2017-00572, Paper 36 (PTAB Jul. 13, 2017); Covidien LP v. Univ. of Florida Research Found. Inc., IPR2016-01274, IPR2016-01275, IPR2016-01276, Paper 21 (PTAB Jun. 28, 2016); see also Kiowa Tribe of Okla. v. Mfg. Techs., Inc., 523 U.S. 751, 754 (1998) (“As a matter of federal law, an Indian tribe is subject to suit only where Congress has authorized the suit or the tribe has waived its immunity.”).

3  Mylan Pharmaceuticals Inc. v. Saint Regis Mohawk Tribe, IPR2016-01127-01132, Paper 129 (Feb. 23, 2018).

Share This Insight

Previous Entries

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.